HC Wainwright reaffirmed their buy rating on shares of Evotec (NASDAQ:EVO - Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a $8.00 target price on the stock.
A number of other analysts have also recently weighed in on EVO. Jefferies Financial Group cut Evotec from a "buy" rating to a "hold" rating and lowered their price target for the company from $8.70 to $3.80 in a research report on Monday, October 7th. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a "hold" rating to a "sell" rating in a report on Thursday, August 8th. Finally, Morgan Stanley downgraded Evotec from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $15.00 to $6.00 in a report on Monday, July 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Evotec presently has an average rating of "Hold" and an average target price of $5.93.
Read Our Latest Stock Analysis on EVO
Evotec Price Performance
Shares of Evotec stock traded up $0.39 on Thursday, reaching $4.26. The stock had a trading volume of 392,453 shares, compared to its average volume of 113,098. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.83 and a quick ratio of 1.73. The business's 50-day moving average price is $3.50 and its two-hundred day moving average price is $4.25. Evotec has a fifty-two week low of $2.85 and a fifty-two week high of $12.00.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of EVO. Novo Holdings A S acquired a new position in shares of Evotec during the 2nd quarter worth about $71,183,000. Mediolanum International Funds Ltd acquired a new position in shares of Evotec during the third quarter worth about $512,000. DCF Advisers LLC grew its stake in shares of Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock worth $552,000 after acquiring an additional 67,156 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in Evotec in the 3rd quarter valued at $104,000. Finally, Cetera Advisors LLC bought a new stake in Evotec during the first quarter worth about $188,000. Institutional investors and hedge funds own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
